"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary.

Manfredi Rizzo, Matilda Florentin, Giatgen A. Spinas, Dimitri P. Mikhailidis, Moses Elisaf, Bruce Griffin, Evangelos Liberopoulos, Kaspar Berneis, Alexandros D. Tselepis, Gerald H. Tomkin, Vasilios Athyros, Klaus G. Parhofer, Jacqueline De Graaf, Alberto Zambon, Anthony S. Wierzbicki, Winfried März, Karl Winkler

Risultato della ricerca: Article

132 Citazioni (Scopus)
Lingua originaleEnglish
pagine (da-a)531-532
Numero di pagine2
RivistaCurrent Vascular Pharmacology
Volume9
Stato di pubblicazionePublished - 2011

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cita questo

Rizzo, M., Florentin, M., Spinas, G. A., Mikhailidis, D. P., Elisaf, M., Griffin, B., Liberopoulos, E., Berneis, K., Tselepis, A. D., Tomkin, G. H., Athyros, V., Parhofer, K. G., De Graaf, J., Zambon, A., Wierzbicki, A. S., März, W., & Winkler, K. (2011). "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Current Vascular Pharmacology, 9, 531-532.